Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
Earnings Data
Report Date
Mar 24, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.62Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was overwhelmingly positive, highlighting significant achievements in clinical trials, regulatory alignment, and financial stability. The only notable concern was the reduction in cash reserves prior to the recent capital raise, which has since been addressed.Company Guidance
Successful Phase Two Study for NDV-01
The phase two study of NDV-01 in non-muscle invasive bladder cancer (NMIBC) reported a 92% overall response rate at any time with favorable safety, showing promise as a potential best-in-class treatment.
FDA Alignment on Phase Three Program for NDV-01
Relmada secured FDA alignment on key elements of the phase three program for NDV-01, allowing two distinct and independent registrational tracks, which is an important de-risking milestone.
Strong Financial Position
Relmada has completed a $100 million underwritten finance, ensuring the company is well-capitalized to support operations into 2028.
Reduction in Operating Expenses
Research and development expenses decreased by $7.1 million and general and administrative expenses decreased by $5.6 million compared to the prior year.
Appointment of Key Personnel
The appointment of Dr. Raj S. Pruthi as Chief Medical Officer and other advisory board members strengthens the company’s focus on advancing novel therapies for NMIBC.
RLMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RLMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $3.88 | $3.95 | +1.80% |
Aug 07, 2025 | $0.60 | $0.59 | -1.67% |
May 12, 2025 | $0.40 | $0.39 | -2.50% |
Mar 27, 2025 | $0.30 | $0.30 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Relmada Therapeutics Inc (RLMD) report earnings?
Relmada Therapeutics Inc (RLMD) is schdueled to report earning on Mar 24, 2026, After Close (Confirmed).
What is Relmada Therapeutics Inc (RLMD) earnings time?
Relmada Therapeutics Inc (RLMD) earnings time is at Mar 24, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RLMD EPS forecast?
RLMD EPS forecast for the fiscal quarter 2025 (Q4) is -0.17.